Pharmaceutical Executive August 2016

August 2016 | Volume 36, Issue 8
Pharmaceutical Executive August 2016
From the Editor
William Looney compares 2002 approaches in boosting shareholder value to those of today. The fall in one particular performance metric is telling.
Columns
Analysts examine investment and business factors that shape supply disruptions. Jill Wechsler reports.
Balancing today’s health data demands and patient privacy is not about new regulations—it’s taking a risk-based approach.
In the spirit of the Olympics, Casey McDonald cites some of the feel-good and not-so-good stories making waves in the competitive world of pharma.
A look at the EU plans for a European patent, and where the UK fits in the mix.
The chances are slim, but a new resolution in Europe on the subject could drum up support for a Brexit-like scenario.
Features
Our latest industry review of shareholder value reveals a sharp performance differential between companies with specialized therapeutic focus and those relying on line diversity, size and scale. By Bill Trombetta.
Pharm Exec convenes some of the industry’s top business development professionals and negotiators to talk about the current climate for biophamara dealmaking.
AmerisourceBergen supply chain leader Peyton Howell discusses the latest trends in pharmaceutical distribution.
Special Sponsored Section
By Pharmaceutical Executive Editors
Although Hungary has posted the third-highest economic growth rate in the EU since 2014, its healthcare system is struggling—dictating the need for new efforts if the country is to regain its dominance as a central and eastern European-region trailblazer in the life sciences.
native1_300x100
lorem ipsum